Guggenheim has upgraded Johnson & Johnson (JNJ) from Neutral to Buy as of September 22, 2025. This change in rating underscores a more optimistic view on the company's future prospects. The current share price stands at $205.62.
Johnson & Johnson, a major player in the pharmaceuticals industry, is involved in the research, development, manufacture, and sale of healthcare products. The company operates through two main segments: Innovative Medicine and MedTech. Its Innovative Medicine segment focuses on various therapeutic areas, including immunology and oncology, while the MedTech segment offers products in categories like cardiovascular and orthopedics.
As of November 20, 2025, Johnson & Johnson boasts a market capitalization of $486.4 billion and a P/E ratio of 19.37. The company reported earnings per share (EPS) of $10.36 and has a dividend yield of 256.8%. Upcoming earnings are anticipated on July 14, 2026, with an EPS estimate of $2.93 and revenue expected to reach $25.1 billion.
Analyst ratings serve as professional opinions based on extensive research. While they can provide valuable insights, they reflect assumptions that may not always come to fruition. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, when making decisions. Analyst views should complement other research rather than serve as the sole basis for investment choices.
It's important to note that analyst ratings can fluctuate as new information emerges, and differing opinions may arise among analysts regarding the same company.